Zacks: Analysts Expect Mediwound Ltd (MDWD) to Announce -$0.16 Earnings Per Share

Brokerages expect that Mediwound Ltd (NASDAQ:MDWD) will report earnings of ($0.16) per share for the current quarter, according to Zacks. Three analysts have provided estimates for Mediwound’s earnings, with the lowest EPS estimate coming in at ($0.17) and the highest estimate coming in at ($0.14). Mediwound reported earnings per share of ($0.09) during the same quarter last year, which would suggest a negative year over year growth rate of 77.8%. The firm is scheduled to announce its next earnings results on Tuesday, February 20th.

According to Zacks, analysts expect that Mediwound will report full-year earnings of ($1.06) per share for the current fiscal year, with EPS estimates ranging from ($1.11) to ($1.01). For the next year, analysts expect that the business will post earnings of ($0.68) per share, with EPS estimates ranging from ($1.16) to ($0.44). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Mediwound.

Mediwound (NASDAQ:MDWD) last issued its quarterly earnings data on Thursday, November 16th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.03. Mediwound had a negative return on equity of 246.58% and a negative net margin of 904.26%.

Several analysts have recently commented on MDWD shares. Oppenheimer set a $10.00 price objective on Mediwound and gave the company a “buy” rating in a report on Thursday, November 16th. Zacks Investment Research upgraded Mediwound from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a report on Wednesday, October 4th. Jefferies Group restated a “buy” rating and issued a $10.00 target price on shares of Mediwound in a research note on Thursday, September 28th. Cowen initiated coverage on Mediwound in a research note on Thursday, September 28th. They issued an “outperform” rating and a $9.00 target price for the company. Finally, SunTrust Banks set a $9.00 target price on Mediwound and gave the stock a “buy” rating in a research note on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Mediwound presently has an average rating of “Hold” and a consensus price target of $9.13.

Shares of Mediwound (NASDAQ MDWD) opened at $4.45 on Friday. Mediwound has a twelve month low of $4.15 and a twelve month high of $8.25. The company has a market capitalization of $120.36, a price-to-earnings ratio of -4.54 and a beta of -0.01.

Hedge funds have recently modified their holdings of the stock. Nationwide Fund Advisors purchased a new position in Mediwound in the 3rd quarter worth $1,538,000. Migdal Insurance & Financial Holdings Ltd. raised its stake in Mediwound by 9.5% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,220,972 shares of the biopharmaceutical company’s stock worth $11,882,000 after acquiring an additional 192,860 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in Mediwound in the 3rd quarter worth $2,140,000. Finally, Wells Fargo & Company MN raised its stake in Mediwound by 23.5% in the 2nd quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock worth $447,000 after acquiring an additional 12,522 shares during the last quarter. Institutional investors own 29.46% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://stocknewstimes.com/2018/01/21/zacks-analysts-expect-mediwound-ltd-mdwd-to-announce-0-16-earnings-per-share.html.

About Mediwound

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply